GSK’s boss said she was ‘highly confident’ sales will top £40billion by 2031 as the group cashes in on speciality medicines for cancer, HIV and other conditions.
With the pharmaceuticals giant’s HIV business as well as respiratory and oncology divisions recording double-digit revenue growth, Emma Walmsley said sales and profits are on course to be ‘towards the top end’ of expectations.
Revenues rose 5 per cent to £15.5billion in the first half of the year and profits were up 41 per cent to £4.2billion.
Shrugging off the impact of US tariffs, Walmsley added: ‘With the breadth of our current business and the growth opportunities we have in our pipeline, we are highly confident in our outlook for sales of more than £40billion by 2031.’
The updated guidance had taken into account the tariffs implemented and expected tariffs on European goods.
Upbeat: GSK boss Emma Walmsley (pictured) said sales and profits are on course to be ‘towards the top end’ of expectations
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
InvestEngine
InvestEngine
Account and trading fee-free ETF investing
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.
This article was originally published by a www.dailymail.co.uk . Read the Original article here. .